Taysha Gene Therapies (TSHA) Tops Q3 EPS by 19c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.64), $0.19 better than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Bernstein sees downside risk to Apple's December quarter results
• BMS Zenbexus doubles response rates in myeloma trial